We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gen-Probe Purchases Prodesse for US$60 Million

By LabMedica International staff writers
Posted on 15 Oct 2009
Print article
Gen-Probe Inc. (San Diego, CA, USA) has signed an agreement to acquire Prodesse Inc., (Waukesha, WI, USA) for approximately $60 million in cash. Gen-Probe's purchase price could increase to up to $85 million if Prodesse achieves certain financial and regulatory milestones in 2010 and 2011.

In connection with the acquisition, Gen-Probe and Prodesse have signed an agreement under which Gen-Probe's sales representatives in the United States, Canada, and Europe will begin copromoting Prodesse's products.

Prodesse develops molecular diagnostic reagents for a variety of infectious disease applications. Prodesse sells three U.S. Food and Drug Administration (FDA; Silver Spring, MD, USA) 510(k) cleared products in the United States, and two additional CE-marked products in Europe. The company's products can be used in conjunction with various nucleic acid extraction and real-time polymerase chain reaction (PCR) platforms, including Cepheid's (Sunnyvale, CA, USA) SmartCycler II System.

ProFlutest, a Prodesse molecular test, was cleared by the FDA in January 2008 for the detection and discrimination of Influenza A Virus, Influenza B Virus, and Respiratory Syncytial Virus. Test results can be obtained in as little as three hours using the assay--a significant improvement over culture-based methods. Prodesse also sells FDA-approved, real-time PCR assays for the clinical diagnosis of Clostridium difficile, a bacteria that is the most serious cause of antibiotic-associated diarrhea, and human metapneumovirus, a common cause of lower respiratory infection in children.

Gen-Probe develops, manufactures, and markets nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. "We believe acquiring Prodesse supports our strategic focus on commercializing differentiated molecular tests for infectious diseases," said Carl Hull, Gen-Probe's president and CEO. "The acquisition is expected to boost our near-term earnings and revenue growth by providing additional leading-edge assays for our experienced sales force to promote to our global customer base."

Related Links:

Gen-Probe Inc.
Prodesse Inc.
U.S. Food and Drug Administration
Cepheid



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Malaria Rapid Test
OnSite Malaria Pf/Pan Ag Rapid Test
New
Silver Member
Apolipoprotein A-I Assay
Apo A-I Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.